Skip to main content
Premium Trial:

Request an Annual Quote

Prostate Cancer's Time to Shine


The past decade has seen plenty of breakthroughs and new drugs for breast cancer, says The Economist. The next decade should do the same for prostate cancer. "Better understanding of the biology of the disease, and particularly of the role of testosterone in promoting it, has stimulated a new era of drug development, reminiscent of the revolution that ushered in Herceptin," the article says. "Some of the therapies remain conceptual, almost to the point of fantasy: a genetically engineered virus that could destroy prostate-cancer cells from within, for example. Several, though, are already available, or are just about to be." For example, Sanofi has developed cabazitaxel, a relative of taxol, which is used to treat breast and ovarian cancer. "It works by preventing the formation of structures called microtubules, which pull the chromosomes apart in dividing cells (such as cancer cells)," The Economist says. There's also Johnson & Johnson's abiraterone, which works by interfering with testosterone production. And there are others — even treatments for castration-resistant prostate cancer, like dendritic cell vaccines.

"Cost, indeed, is a consideration for others among the new anti-prostate cancer treatments," The Economist says. "But Herceptin, too, was subject to scrutiny about its cost at the beginning. Now Herceptin treatment is routine, and many women’s lives are the better (and longer) for it. With luck, in a few years' time, men will be able to say the same."

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.